
PAC
CAS No. 2158322-33-7
PAC ( Compound PAC1 )
产品货号. M13446 CAS No. 2158322-33-7
PAC1(化合物 PAC1)是一种新型 PROTAC 抗体偶联物,与未偶联抗体的 PROTAC 相比,它是更有效的雌激素受体-α (ERα) 降解剂。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称PAC
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述PAC1(化合物 PAC1)是一种新型 PROTAC 抗体偶联物,与未偶联抗体的 PROTAC 相比,它是更有效的雌激素受体-α (ERα) 降解剂。
-
产品描述PAC1 (Compound PAC1) is a novel PROTAC antibody conjugate, more potent estrogen receptor-alpha (ERα) degrader compared to PROTAC without antibody conjugation.
-
体外实验Treatment of HER2 expressing cells with HER2 antibody containing PAC Anti-HER2(Endox-XIAP) results in a marked decreased Estrogen Receptor-alpha (ERα) levels with an IC50 of 132 ng/mL. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding group (“E3LB”), a linker (“L2”) and a protein binding group (“PB”). The following sections describe the components that comprise the PAC. To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A“linker” (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D) .
-
体内实验——
-
同义词Compound PAC1
-
通路PROTACs
-
靶点PROTAC
-
受体PROTAC
-
研究领域——
-
适应症——
化学信息
-
CAS Number2158322-33-7
-
分子量1674.93
-
分子式C94H107N13O16
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 70 mg/mL (41.79 mM)
-
SMILESCCC(=C(C1=CC=C(C=C1)OCCN(C)C(=O)COCCOCCNC(=O)C2=CC=C(C=C2)C(=O)N3C(C(C(=O)N(C4=C3C=C(C=C4)C#N)CC5=C(C=CC6=CC=CC=C65)OC)NC(=O)C(C)NC)C)C7=CC=C(C=C7)OCC8=CC=C(C=C8)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN9C(=O)C=CC9=O)C1=CC=CC=C1
-
化学全称4-((2S,3S)-8-Cyano-5-((2-methoxynaphthalen-1-yl)methyl)-2-methyl-3-((S)-2-(methylamino)propanamido)-4-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-1-carbonyl)-N-(2-(2-(2-((2-(4-((Z)-1-(4-((4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexan
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
产品手册




关联产品
-
BETd-246
一种有效的第二代 BET 蛋白质降解剂,具有卓越的选择性、效力和抗肿瘤活性。
-
JH-XI-10-02
JH-XI-10-02 是一种基于 CDK8 抑制剂 JH-VIII-49 的 CDK8 PROTAC,可诱导 Jurkat 细胞中 CDK8 部分降解,IC50 为 159 nM。
-
BETd-260 trifluoroac...
BETd-260 三氟乙酸酯(ZBC260、BETd 260 TFA)是一种新型 PROTAC BET 降解剂,可将 HJB97 与 E3 泛素连接酶 VHL 的配体连接。